Bruce Levine, Ph.D.
The Clinical Cell and Vaccine Production Facility facilitates the translation of research, from bench to bedside, of novel allogeneic and autologous cellular-based vaccines and related experimental immunotherapies. Specifically, it provides specialized scientific, technical, and regulatory expertise in immune cell engineering and Good Manufacturing Practice (GMP). Cellular vaccines and other immunotherapies developed at the Facility are reinfused to patients enrolled in Penn clinical trials that have been approved by the FDA and the Cancer Center's Clinical Trials Scientific Review and Monitoring Committee.
For a full description of this service, please visit the Core's website: http://www.med.upenn.edu/bmcrc/CCVPF?CCVPF